Literature DB >> 28548545

Mild chronic obstructive pulmonary disease: why spirometry is not sufficient!

Amany F Elbehairy1,2, Grace Parraga3, Katherine A Webb1, J Alberto Neder1, Denis E O'Donnell1.   

Abstract

INTRODUCTION: Chronic obstructive pulmonary disease (COPD) - an inflammatory disease of the airways, alveoli and lung microvasculature - is a leading cause of death worldwide. Smokers with milder airway obstruction constitute the majority of patients with this disease. Many studies have shown increased morbidity, activity-related dyspnea, exercise intolerance and mortality in such patients, compared with age-matched healthy populations. Clinical evaluation of symptomatic smokers with ostensibly mild airway obstruction poses a challenge in clinical practice as spirometry can obscure extensive heterogeneous pathophysiological impairment. Areas covered: A detailed review of the evidence for complex biological, physiological and radiological abnormalities in smokers who barely fit arbitrary spirometric criteria for COPD diagnosis. A brief discussion of the debate about current diagnostic spirometric criteria for COPD that can lead to diagnostic confusion and, in-some-instances, to inappropriate management. Finally, we provide a review of the clinical implications of these structural and functional abnormalities and try to build a solid rationale for earlier detection and effective, timely management. Expert commentary: The prevalence of mild COPD among smokers is high, yet under-diagnosis remains a major problem and there is lack of evidence-based management recommendations for this sub-population. Further tests beyond spirometry are useful in uncovering patho-physiological derangements that are clinically relevant.

Entities:  

Keywords:  Mild COPD; dyspnea; exercise; imaging; small airway remodeling; spirometry; vascular injury

Mesh:

Year:  2017        PMID: 28548545     DOI: 10.1080/17476348.2017.1334553

Source DB:  PubMed          Journal:  Expert Rev Respir Med        ISSN: 1747-6348            Impact factor:   3.772


  5 in total

1.  Deep neural network analyses of spirometry for structural phenotyping of chronic obstructive pulmonary disease.

Authors:  Sandeep Bodduluri; Arie Nakhmani; Joseph M Reinhardt; Carla G Wilson; Merry-Lynn McDonald; Ramaraju Rudraraju; Byron C Jaeger; Nirav R Bhakta; Peter J Castaldi; Frank C Sciurba; Chengcui Zhang; Purushotham V Bangalore; Surya P Bhatt
Journal:  JCI Insight       Date:  2020-07-09

2.  At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.

Authors:  Fernando J Martinez; MeiLan K Han; James P Allinson; R Graham Barr; Richard C Boucher; Peter M A Calverley; Bartolome R Celli; Stephanie A Christenson; Ronald G Crystal; Malin Fagerås; Christine M Freeman; Lars Groenke; Eric A Hoffman; Mehmet Kesimer; Kostantinos Kostikas; Robert Paine; Shahin Rafii; Stephen I Rennard; Leopoldo N Segal; Renat Shaykhiev; Christopher Stevenson; Ruth Tal-Singer; Jørgen Vestbo; Prescott G Woodruff; Jeffrey L Curtis; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2018-06-15       Impact factor: 21.405

Review 3.  What will Happen in the World of COPD 2030?

Authors:  Richard E K Russell; Mona Bafadhel
Journal:  Turk Thorac J       Date:  2019-07-30

4.  Significance of FEV3/FEV6 in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.

Authors:  Nathan Yee; Daniela Markovic; Russell G Buhr; Spyridon Fortis; Mehrdad Arjomandi; David Couper; Wayne H Anderson; Robert Paine; Prescott G Woodruff; Meilan K Han; Fernando J Martinez; R Graham Barr; James M Wells; Victor E Ortega; Eric A Hoffman; Victor Kim; M Bradley Drummond; Russell P Bowler; Jeffrey L Curtis; Christopher B Cooper; Donald P Tashkin; Igor Z Barjaktarevic
Journal:  Chest       Date:  2021-11-10       Impact factor: 10.262

5.  Use of cardiopulmonary exercise testing to assess early ventilatory changes related to occupational particulate matter.

Authors:  T P Chao; E F Sperandio; T L V P Ostolin; V R Almeida; M Romiti; A R T Gagliardi; R L Arantes; V Z Dourado
Journal:  Braz J Med Biol Res       Date:  2018-03-26       Impact factor: 2.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.